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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYStem cell-derived somatic cells represent an unlimited resource for basic and translational science. Although promising, there are signif-
icant hurdles that must be overcome. Our focus is on the generation of the major cell type of the human liver, the hepatocyte. Current
protocols produce variable populations of hepatocytes that are the product of using undefined components in the differentiation process.
This serves as a significant barrier to scale-up and application. To tackle this issue, we designed a defined differentiation process using
recombinant laminin substrates to provide instruction. We demonstrate efficient hepatocyte specification, cell organization, and signif-
icant improvements in cell function and phenotype. This is driven in part by the suppression of unfavorable gene regulatory networks
that control cell proliferation and migration, pluripotent stem cell self-renewal, and fibroblast and colon specification. We believe that
this represents a significant advance, moving stem cell-based hepatocytes closer toward biomedical application.INTRODUCTION
Significant advances in cell-based therapies, particularly in
the liver, represent promising alternatives to whole-organ
transplantation. Cell transplantation has several benefits
over organ transplantation, including the use of one organ
for several patients, and the procedure itself is generally less
invasive. Although significant progress has beenmade, im-
mune system clearance and cell-based therapy reliance
upon organ donations are significant limitations. As a
result, obtaining a potentially unlimited supply of somatic
cells from defined genetics for cell-based therapy is an
intense area of study.
Pluripotent stem cells are particularly promising cell
types, possessing the ability to self-replicate and differen-
tiate into all cell types in the body, including hepatocytes
(Sun et al., 2013). This promises in theory an ‘‘off-the-
shelf’’ alternative to donated tissue. Differentiation proce-
dures have advanced over the last decade, and efficient
protocols to generate stem cell-derived hepatocyte-like
cells (HLCs) from either human embryonic stem cells
(hESCs) or induced pluripotent stem cells (iPSCs) now
exist (Lavon et al., 2004; Hay et al., 2007, 2008, 2011;
Cai et al., 2007; Duan et al., 2007; Basma et al., 2009; Sul-
livan et al., 2010; Touboul et al., 2010; Si-Tayeb et al.,
2010; Rashid et al., 2010; Payne et al., 2011; Zhou et al.,
2012, 2014; Medine et al., 2013; Takayama et al., 2013a;
Szkolnicka et al., 2014a). These procedures utilize growth1250 Stem Cell Reports j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 Thfactors, mimicking each stages of embryonic develop-
ment, and can deliver homogenous populations of
HLCs. Although these prototype systems have provided
confidence in pluripotent stem cell technologies, their
amenability to defined scale-up with clinical-grade hESC
lines has not been achieved.
HLCs derived from pluripotent stem cells have shown
significant promise in vitro, accurately modeling human
drug exposure (Medine et al., 2013; Szkolnicka et al.,
2014b; Holmgren et al., 2014; Ware et al., 2015). HLCs
have also been employed to study the hepatitis C virus
life cycle (Wu et al., 2012; Roelandt et al., 2012; Zhou
et al., 2014, Carpentier et al., 2014) and, more recently,
the malaria parasite (Ng et al., 2015). HLCs have also
been derived from patients with monogenic metabolic
liver diseases and have been shown to recapitulate features
of a1-antitrypsin deficiency, familial hypercholesterole-
mia, and glycogen storage disease (Rashid et al., 2010).
The ability to generate population-specific HLCs that accu-
rately represent adult liver tissue has significant implica-
tions in the drug development process and in stratifying
patient healthcare.
Despite these advances, HLCs derived from pluripotent
stem cells still display an immature phenotype (Godoy
et al., 2015; Forbes et al., 2015). This phenotypic immatu-
rity has contributed to the limited the use of stem cell-
derived hepatocytes for clinical application (Schwartz
et al., 2014). Efforts to address this have utilized naturale Authors
Figure 1. Differentiation Protocol
(A) Phase contrast images of representative
fields of view at each key stage during dif-
ferentiation (magnification, 310). Scale
bars, 100 mm.
(B) Cell types present at differentiation
stage.
(C) Growth factors or molecules and media
used at each stage. MG, Matrigel; DE, defini-
tive endoderm; SR, serum replacement; HC,
hydrocortisone.
(D) Timescale of the process.and synthetic culture substrates to improvemature hepato-
cyte function and enhance stability (Takayama et al.,
2013b; Jitraruch et al., 2014; Villarin et al., 2015). Other
studies have used small molecules to replace growth factors
to drive down the cost of the method (Hay et al., 2007,
2008; Siller et al., 2015); however, those publishedmethods
both still rely upon the use of undefined components,
highlighting the need to develop defined systems.
A critical component of in vitro maintenance and differ-
entiation systems is extracellular matrix (ECM) support.
The ECM elicits profound effects on cell behavior. In the
human stem cell self-renewal and differentiation fields,
the mouse sarcoma-derived Matrigel represents the most
extensively used ECM. AlthoughMatrigel has undoubtedly
been enabling for the stem cell field, its relatively unde-
fined nature and significant batch-to-batch variability
results in difficulties to generate reliable, reproducible
cultures of HLCs. Moreover, if HLCs are to be utilized clin-
ically, then this process must meet good manufacturing
process (GMP) guidelines. To comply with this, products
containing animal derivatives are strictly controlled.
Therefore, to overcome variability, and in an effort to
define our differentiation process, we employed two re-
combinant full-length human laminins and compared
those with Matrigel in three hESC lines, two of which are
available at GMP-grade.
The laminins used in our systemwere selected because of
their importance in the developing embryo (Domogat-
skaya et al., 2012; Miner et al., 2004), the regenerating liver
(Martinez-Hernandez and Amenta, 1995; Carlsson et al.,
1981), and the liver stem cell niche (Tanimizu et al.,
2012; Lorenzini et al., 2010). Additionally, the laminins
employed in this study are known to support the clonal
expansion of hESCs (Rodin et al., 2010) and drive endo-Stem Cell Repdermal differentiation (Taylor-Weiner et al., 2013) and liver
stem cell differentiation (Takayama et al., 2013a), making
them ideal candidate substrates for our purposes. Although
endoderm and liver stem cell differentiation has been
achieved, neither of the laminin matrices employed, in
isolation or mixed format, have been shown to support
hepatocyte differentiation from research- and GMP-grade
hESC lines.
Utilizing pure laminin 521 (L521) and the blend of lam-
inins 521 and 111 as substrates for hESC-derived differenti-
ation, we demonstrate efficient hepatocyte specification
and significant improvements in cell function and pheno-
type. Furthermore, stem cell-derived hepatocytes derived
on laminin surfaces formed organized structures, and their
gene regulatory networks were closer to that of freshly iso-
lated human hepatocytes. We believe that these studies
represent a significant advance toward the large-scale
production of clinical-grade and quality-assured human
hepatocytes from GMP hESCs.RESULTS
Differentiation of Pluripotent Stem Cells Toward
Hepatocytes
hESCs were replated onto Matrigel and wells coated with
pure laminin 521 and the laminin 521:111 mix (1:3 ratio,
hereafter referred to as laminin 111 mix [L111]). hESCs
were differentiated using our standard protocol, outlined in
Figure 1, and analyzed at key time points. hESCs on all three
matrices adhered, proliferated, and differentiated intoHLCs.
Twenty-four hours after replating, hESCs were examined
for characteristic colony morphology and stem cell-associ-
ated marker expression (Figure S1). hESCs displayed theorts j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 The Authors 1251
Figure 2. Gene Expression during Differ-
entiation
(A–F) Gene expression of the pluripotency-
associated markers (A) OCT4 and (B) NANOG,
the endoderm/hepatoblast markers (C)
FOXA2 and (D) a fetoprotein (AFP), (E) he-
patocyte nuclear factor-4-a (HNF4A), and
(F) albumin (ALB) was analyzed on days 0, 3,
9, and 18, normalized to the housekeeping
gene GAPDH, and expressed relative to
hESCs. The results shown represent three
biological replicates, and error bars repre-
sent SD. *p < 0.05, **p < 0.01; one-way
ANOVA with Tukey post hoc test.appropriate embryonic stem cell morphology, with subtle
differences detected on each matrix (Figure S1A). Impor-
tantly, themajority of hESCs expressed the stemcellmarkers
Oct4 and Nanog when attached to Matrigel (88.3% ± 4.8%
and 86.7% ± 5.0%, respectively), laminin 521 (93.2% ±
5.9% and 88.7% ± 5.4%, respectively), and laminin 111
mix (93.8% ± 2.4% and 90.4% ± 3.5%, respectively) (Fig-
ure S1B; Table S1). These results were corroborated by qPCR
(Figures 2A and 2B).
Twenty-four hours after replating, differentiation was
initiated using a serum-free procedure (Szkolnicka et al.,1252 Stem Cell Reports j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 Th2014a; Cameron et al., 2015). Cell extracts were collected,
and mRNA was assessed at the denoted time points (Fig-
ure 2; Table S2). All differentiation procedures delivered
cell populations that transited from pluripotency, through
definitive endoderm, to hepatoblast-like cells, and, subse-
quently, hepatocytes, as demonstrated by qPCR (Figure 2).
The pluripotency-associated markers OCT4 (Figure 2A)
and NANOG (Figure 2B) decreased over time on all sub-
strates. The endoderm-associated gene FOXA2 peaked on
all substrates on day 3 and then decreased thereafter (Fig-
ure 2C). Expression of AFP varied across all substratese Authors
Figure 3. Endoderm and Hepatic Specification
(A and B) FOXA2 (A) and SOX17 (B) stained cells on MG, laminin
521, and laminin 111 on day 3 of differentiation. Cells were
counterstained with Hoechst 33342. The percentage of positive
cells and SD are shown. Images were taken at 320 magnification.
(C–E) AFP (C), HNF4a (D), and CK19 (E) on MG, laminin 521, and
laminin 111 on day 9 of differentiation. Cells were counterstained
with Hoechst 33342. Data are presented as the mean of three
independent experiments ± SD.
All images were taken at 310 magnification.(Figure 2D). Cells on Matrigel and laminin 521 followed
the same trend in expression, peaking on day 9 and
then decreasing on day 18. Conversely, cells on the lami-
nin 111 mix gradually increased in AFP expression over
time, peaking on day 18. HNF4A was detected as early as
day 3 on all substrates (Figure 2E). By day 9, differences
in expression patterns emerged. On Matrigel and laminin
521, HNF4A was highest on day 9 and decreased on day
18, whereas, on the laminin 111 mix, on day 18,Stem Cell RepHNF4A expression was increased. Variation in HNF4A
gene expression was observed between experimental rep-
licates. However, this did not appear to affect downstream
differentiation and was not reflected in HNF4a protein
levels (Figures 3 and 6).
Expression of ALB was upregulated from day 9 across all
substrates (Figure 2F). Levels ofALB from days 9–18 saw the
highest increase on the laminin 111 mix (10,000-fold),
significantly higher than on Matrigel (p < 0.001) and lam-
inin 521 (p < 0.001).
Human Embryonic Stem Cell-Derived Hepatoblast
Specification
Although our previous data provided encouragement that
stem cell differentiation was proceeding as we would
expect, our next objective was to test the efficiency of the
process on human recombinant laminin 521 and the lam-
inin 111 mix in comparison with Matrigel (Figure 3).
Human embryonic stem cell (ESC)-derived endoderm spec-
ification was measured using two commonly used endo-
derm-associated markers: FoxA2 and Sox17. The majority
of cells on Matrigel, laminin 521, and laminin 111 mix
were positive for FoxA2, with 82.8% ± 2.1%, 80.4% ±
3.5%, and 88.1% ± 2.3% cells positive, respectively (Fig-
ure 3A). Sox17 staining was more varied across the three
matrices. It was lowest on Matrigel (74.8% ± 8.3%) and
higher on laminin 521 (92.6% ± 1.8%) and the laminin
111mix (87.2% ± 6.9%) (Figure 3B). As differentiation pro-
gressed and hepatic fate was specified (by day 9), cells
began expressing high levels of hepatoblast markers. AFP
was expressed in the majority of cells on Matrigel
(90.8% ± 1.1%), laminin 521 (98.3% ± 0.9%), and the lam-
inin 111 mix (95.3% ± 2.0%) (Figure 3C). The trend was
similar for HNF4A, with the majority of cells expressing
the transcription factor on Matrigel (88.5% ± 2.5%),
laminin 521 (86.4% ± 2.3%), or the laminin 111 mix
(85.9% ± 1.8%) (Figure 3D). CK19 expression was also
observed in the majority of cells differentiated on Matrigel
(96.8% ± 2.0%), laminin 521 (98.5% ± 1.0%), and the lam-
inin 111mix (97.2% ± 1.5%) (Figure 3E). Hepatoblast spec-
ification on all three matrices appeared to be equivalent
and highly efficient, and the initial differences in hESC
morphology observed on the three matrices did not appear
to affect the kinetics or the efficiency of cellular differenti-
ation. However, we did observe an 2-fold increase in cell
size in HLCs differentiated on the laminin 111 mix and
521 substrates (Figure 3E, CK19).
Human Embryonic Stem Cell-Derived Hepatocyte
Specification and Maturation
Post-hepatoblast specification, cell cultures were differenti-
ated toward hepatocytes, and, on day 18, hepatocyte spec-
ification was assessed by immunostaining for albumin andorts j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 The Authors 1253
Figure 4. Hepatocyte Maturation
(A–C) Albumin (A), E Cadherin (B), and cellular proliferation marker
(Ki67, C) staining of cells on MG, laminin 521, and laminin 111 on
day 18 of differentiation. Cells were counterstained with Hoechst
33342. Data are presented as the mean of three independent
experiments ± SD. All images were taken at 310 magnification.E-cadherin. Notably, similar patterns of protein production
in the Matrigel and laminin populations were observed
(Figure 4). Albumin staining was detected in HLCs on
Matrigel (91.6% ± 0.7%), laminin 521 (89.5% ± 8.7%),
and the laminin 111 mix (91.3% ± 4.0%) (Figure 4A).
Next, E-cadherin (E CAD) expression was assessed because
of its importance in cell-to-cell contact (Treyer and Mu¨sch,
2013) and low-level expression in fetal hepatocytes (Stama-
toglou et al., 1992). On Matrigel and the laminin 111 mix,
E-cadherin was expressed in 76.5% (± 0.7%) of cells and
73.7% (± 3.7%), whereas HLCs on laminin 521 were
67.4% (± 4.4%) positive (Figure 4B). Although immuno-
staining studies showed equivalence between the cell pop-
ulations, differences in cell proliferation were observed on
the different substrates. Of note, HLCs derived on Matrigel
demonstrated an increase in the cell proliferation marker
Ki67, with 29.8% (± 3.7%) of HLCs staining positive. This
was in contrast to 17.4% (± 6.2%) of positive HLCs on
laminin 521 and 15.9% (± 6.6%) on the laminin 111 mix
(Figure 4C).
Human Embryonic Stem Cell-Derived Hepatocyte and
Primary Hepatocyte Function
Given that cell division is an important factor in hepato-
cyte function, we studied hepatocyte metabolic capacity1254 Stem Cell Reports j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 Thin vitro. Stem cell-derived hepatocytes were examined for
cytochrome P450 expression using well characterized anti-
sera. CYP2D6 andCYP3A expressionwas detected in 84.4%
(± 2.1%) and 95.4% (± 2.6%) of HLCs derived on Matrigel
(Figures 5A and 5B). On laminin 521, 85.7% (± 5.7%) of
cells expressed CYP2D6 and 91.3% (± 3.7%) expressed
CYP3A (Figures 5A and 5B). On the laminin 111 mix,
82.5% (± 5.0%) cells were positive for CYP2D6, and
90.6% (± 2.9%) of cells were positive for CYP3A (Figures
5A and 5B). Although protein expression appeared to be
equivalent, stem cell-derived hepatocyte CYP P450 func-
tion varied (Figure 5C). On the laminin 111 mix, CYP1A2
activity increased over time and was significantly higher
than on Matrigel at all time points. On laminin 521,
CYP1A2 was elevated at all time points and was signifi-
cantly greater than on Matrigel cultures on days 24 and
26 of differentiation. CYP3A function was increased up to
25-fold on the laminin 111 mix (Figure 5C). HLCs on
both laminins exhibited significantly increased metabolic
function relative to cells on Matrigel at all time points. To
corroborate these data, differentiation experiments were
carried out in another hESC line, Manchester 12, available
at GMP-grade (Figure S4). The results obtained demonstrate
that HLCs derived from Manchester 12 (Man12) on
both laminins displayed significantly superior CYP3A and
CYP1A2 function in comparison with Matrigel cultures
(Figure S4).
Following this, stem cell-derived hepatocyte function
was compared with cryopreserved adult hepatocytes. Pri-
mary hepatocyte function varied betweenmale and female
samples (continuous versus dotted line in Figure 5C).
CYP1A2 function was comparable between primary hepa-
tocytes and HLCs generated on the laminin 111 mix
(Figure 5C; Figure S3C), whereas CYP3A function was
significantly superior to primary hepatocytes in HLCs
differentiated on both laminins (Figure 5C; Figure S3C).
Although both H9- and Man12-derived hepatocytes dis-
played improved function on laminin 521 and the laminin
111 mix, H9-derived hepatocytes were closer in terms of
metabolic activity to cryopreserved human hepatocytes
(Figure 5; Figure S4). Despite these changes inmetabolic ca-
pacity, we did not detect any significant differences in albu-
min or a fetoprotein secretion by ELISA (Figure S2). This
was in contrast to another hESC line, Manchester 11
(Man11). Man11-derived hepatocytes did not demonstrate
improved cytochrome P450 activities on laminin 521 and
the 111 mix. However, they did demonstrate organized
features and significantly reduced AFP secretion when
compared with Matrigel, demonstrating a reduction of
fetal-like behavior. In support of this, Man11-derived pop-
ulations also displayed significantly increased albumin
secretion on laminin 521 in comparison with Matrigel
and the laminin 111 mix (Figure S5).e Authors
Figure 5. Metabolic Function and Expres-
sion
(A and B) Expression of CYP2D6 (A) and
CYP3A4 (B) on MG, LN521, and LN111 at day
24 of differentiation. Cells were counter-
stained with Hoechst 33342. Data are pre-
sented as the mean of three independent
experiments ± SD. All images were taken at
310 magnification.
(C) Cytochrome P450 metabolic activity of
CYP1A2 and CYP3A of cells cultured on Ma-
trigel (black columns), laminin 521 (shaded
columns), and the laminin 111 mix (white
columns). Data are presented as mean of six
independent experiments. Error bars repre-
sent SEM.*p < 0.05, **p < 0.01; one-way
ANOVA with Bonferroni post hoc analysis.
The dotted and continuous lines indicates
the average CYP activity of primary hepato-
cytes in culture. PHH(F), primary human
hepatocytes, female; PHH(M), primary hu-
man hepatocytes, male.Human Embryonic Stem Cell-Derived Hepatocyte
Organization
HLCs derived on laminin 521 and the laminin 111mix dis-
played a more primary hepatocyte-like appearance with
very pronounced nuclei that were often bi-nucleate (Fig-
ure 6A). Phase contrast images also indicated that hepato-
cytes were arranged in organized structures within the cul-
ture dish. Around these hepatic clusters, an important basal
membranemarker was detected, multidrug resistance-asso-
ciated protein (MRP-1). Only hepatocytes differentiated on
laminins 521 and the laminin 111 mix exhibited networks
of organized hepatocytes expressing MRP1 in vitro. This
was in stark contrast to cells on Matrigel, which displayed
more individual and punctate staining (Figure 6B). To
determine whether cell organization improved canalicular
function, we examined biliary efflux using 5(6)-carboxy-
20,70-dichlorofluorescein diacetate (CDFDA). Notably, cell
organization was paralleled by more active biliary efflux
in cells differentiated on laminin 521 and the laminin
111 mix versus Matrigel (Figure 6C).Stem Cell RepGenome-wide Analysis
The experiments presented so far demonstrated an
improvement in stem cell differentiation to hepatocytes
on laminins. To understand which gene regulatory net-
works underpinned this, we performed an extensive and
unbiased bioinformatics analysis (Figure 7). For this pur-
pose, hESCs were differentiated on Matrigel (Godoy et al.,
2015), laminin 521, and the laminin 111mix. The standard
differentiation protocol was applied, and whole-genome
expression profiles of three independent experiments
were analyzed. Data were compared with a previous study
(Godoy et al., 2015) that used freshly isolated primary hu-
man hepatocytes (FHs), hESC cells, andMatrigel-differenti-
ated HLCs (day 17 and 21). These data were compared with
stem cell-derived hepatocytes derived onMatrigel, laminin
521, and the laminin 111 mix on day 24 of the differentia-
tion process (day 24, L521 and L111, respectively).
The overview by principal component analysis illustrates
that laminin-directed differentiation shifted HLCs toward
FHs (Figure 7A). The number of differentially expressedorts j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 The Authors 1255
Figure 6. Functional Organization of Hepatocyte-like Cells
(A) Phase contrast images of cells on day 24 of culture on MG,
LN521, and LN111.
(B) Co-immunostaining of MRP-1 (red) and of HNF4a (green).
(C) CDFDA staining shows functional bile canaliculi on laminins,
whereas, on Matrigel, only diffuse staining is seen.
Cells were counterstained with Hoechst 33342, and all images were
taken at310 magnification. The data presented are representative
of three independent experiments.genes in this study (556 betweenMatrigel and laminin 521
and 664 between Matrigel and the laminin 111 mix, false
discovery rate [FDR] adjusted) could be considered major.
To further characterize this difference, we employed
CellNet software (Cahan et al., 2014; Figure 7B). Consistent
with previous studies (Godoy et al., 2015; Morris et al.,
2014), CellNet identified repression of stem cell gene regu-
latory network scores (GRN-ESC) and increased liver and
colon GRNs in stem cell-derived hepatocytes (Figure 7B).
Importantly, CellNet demonstrated a significant decrease
of the hESC- and colon-associated GRNs in laminin- versus
Matrigel-differentiated samples (Figure 7B; Figure S6). Of
the two laminins, the laminin 111 mix showed a signifi-
cantly stronger effect than pure laminin 521 (Figure 7B).
To obtain further insights, we used a recently published
fuzzy clustering technique (Godoy et al., 2015). In the pro-
liferation- and cell migration-associated clusters, laminins
led to a significantly stronger suppression than Matrigel
cultures (clusters III–V; Figure 7C). These results were
confirmed by qPCR with a reduction in E2F7, AURKA,
SOX11, and TFAP2A on laminin versusMatrigel (Figure S6).
A reduction in stem cell (SALL2 and LIN28A) and fibroblast1256 Stem Cell Reports j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 Th(FOXF2) gene expression was also detected by qPCR. In
summary, the main advantage of laminin over Matrigel
was a more efficient suppression of inappropriate GRNs
controlling stem cell biology, colon specification, fibroblast
specification, and cell proliferation andmigration (Figure 7;
Figure S6).
Given the important role of integrins as receptors for
laminins and their ability to bind EGF, an important liver
mitogen, we examined integrin expression and phosphati-
dylinositol 3-kinase (PI3K)-Akt and Jak-STAT signaling in
hepatocytes replated on each ECM. In these analyses, we
focused on the genes in the Kyoto Encyclopedia of Genes
and Genomes (KEGG) categories ‘‘PI3K-AKT Signaling
Pathway,’’ ‘‘JAK-STAT Signaling Pathway,’’ and ‘‘ECM-
Receptor Interaction.’’ KEGG pathway analysis identified
a significant overrepresentation of the aforementioned
KEGG gene clusters in all HLCs (Table S3; Figure S7).
From the bioinformatics analyses, we could not identify
clear changes in GRNs that may be the drivers of enhanced
hepatocyte differentiation on recombinant laminins (Fig-
ure 7B; Figure S7A), and this requires more detailed investi-
gation. Likewise, the ECMs used in our study had subtle
effects on integrin expression. ITGB2 and ITGAL gene
expression was downregulated in comparison with freshly
isolated hepatocytes, whereas other integrins were upregu-
lated, including ITGAV, ITGA3, and ITGB6 (Figure S7C).
Notably, we did detect that integrins ITGA7 and ITGA6
were differentially regulated on laminin versus Matrigel,
and this will be the focus of a future investigation
(Figure S7C).DISCUSSION
The extracellular matrix can have profound effects on
cells, modulating many biological processes, including
cell attachment, migration, proliferation, differentia-
tion repair, and development (Martinez-Hernandez and
Amenta, 1993a, 1993b, 1995). By mimicking key elements
of the liver cell niche using two laminin isoforms, we
dramatically improved hepatocyte differentiation, signifi-
cantly enhancing cell organization and function. Although
similar numbers of HLCs were produced on the three
matrices, distinct differences in HLC phenotype, organiza-
tion, and function were observed. Notably, CYP1A2 and
3A function were equivalent or superior to primary human
hepatocytes when stem cell-derived hepatocytes were
cultured on laminin 521 and the laminin 111 mix, and
this remained stable for several days in culture.
In addition to metabolic function, stem cell-derived
hepatocytes displayed more organized structures on the
laminin substrates. The differences in cell organization
between laminin and Matrigel cultures could have beene Authors
Figure 7. Gene Array Analysis Identifies Genome-Wide Effects of the Laminin Matrix in HLC Differentiation
(A) Principal component analysis of the 1,000 genes with highest variance in hESCs, FHs, and HLCs differentiated on MG for 17, 21, and
24 days or L111 or L521 for 24 days. The results shown represent three biological replicates. The graph shows the two largest principal
components that constitute 86.5% of the variance.
(B) GRN status obtained from the gene expression profile in FHs, ESCs and HLCs on the different matrices. The training score for ESCs, colon,
and liver are shown in dark blue and represent the maximal score for each cell/tissue. The score for the queried samples (in light blue) is
calculated in relation to the maximal cell/tissue specific score, as described in Cahan et al. (2014). Significantly different scores were
observed for laminin 521 and laminin 111 versus Matrigel (day 24) on ESCs and Colon GRNs (***p < 0.005, **p < 0.05, *0.5, t test).
(C) Clustering of genes with similar expression patterns in HLCs generated three superclusters representing the motifs ‘‘mature liver
functions,’’ ‘‘proliferation,’’ and ‘‘ECM/migration’’ (see Supplemental Information for details). Shown are the KEGG and gene ontology (GO)
motifs overrepresented in each gene cluster. Representative genes for each cluster and motif are also indicated. Genes in cluster V were
(legend continued on next page)
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underpinned by the upregulation of key proliferation and
motility genes on Matrigel. With the exception of E2F7,
which was reduced significantly on the laminin 111 mix
only, AURKA, SOX11, and TFAP2A were reduced on both
laminins. E2F7 is an important regulator of hepatocyte pro-
liferation and human telomerase gene expression (Sirma
et al., 2011) and represents a key target in the quest for a
mature and stably differentiated hepatocyte in vitro. Simi-
larly, the suppression of AURKA, SOX11, and TFAP2A,
known to play key roles in cell proliferation, hyperplasia,
and suppression of terminal differentiation, were also sup-
pressed on both laminin substrates (Gadi et al., 2013; Holl
et al., 2011; Lee et al., 2013), representing significant prog-
ress. Enhanced hepatocyte organization on both laminins
was evidenced by MRP1 staining and resulted in improved
canalicular excretion of CDFDA, suggesting a mature
feature stem cell-derived hepatocytes in vitro (Karpen and
Suchy, 2001).
The analysis of liver gene expression and function sug-
gested an improvement of the hepatocyte phenotype on
laminins. We were keen to understand what underpinned
this and employed gene microarrays. Using principal
component analysis, our first goal was to understand
whether the different matrices cause dramatic or only
minor changes in overall gene expression (Godoy et al.,
2009, 2010). The number of differentially expressed genes
in this study could be considered major, with the laminin
111 mix and laminin 521 imparting three specific features
on HLCs compared with Matrigel. First, expression of plu-
ripotency-associated transcripts was more effectively sup-
pressed by laminins. Second, the laminin 111 mix more
efficiently suppressed proliferation and migration-associ-
ated gene expression. Third, induction of unwanted colon-
and fibroblast-associated gene expression, which is an
inherent side effect of the currently used hepatocyte differ-
entiation protocols (Godoy et al., 2015), was ameliorated
by the laminin 111 mix.
Alongside improved function and a decrease in un-
wanted gene expression, these laminins also provide a
xeno-free alternative to Matrigel. As such, serum-free
directed hepatocytes, in combination with laminin 521
or the laminin 111mix, can now be described as ‘‘defined.’’
To test whether our procedure was compatible with hESC
lines available at clinical grade, we employed twoManches-
ter hESC lines (Man11 andMan12). All three lines differen-
tiated efficiently, with themajority of cells expressing albu-
min and CYP3A. The same level of cellular organizationexpressed at lower levels on HLCs in laminin 111 compared with Matrig
in each gene cluster. Data are presented as the mean of three indepen
levels (log2 scale) were observed between Matrigel (day 24), laminin 5
supercluster proliferation (t test, p < 0.005).
1258 Stem Cell Reports j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 Thwas also demonstrated across the GMP lines, with the
HLCs on laminin 521 and the laminin 111 mix displaying
networks of MRP1 staining. Notably, the H9-derived hepa-
tocytes displayed a closer metabolic profile to primary
hepatocytes than Man11- and -12-derived hepatocytes.
However, both laminin 521 and the laminin 111 mix did
improve the Man11 and Man12 HLC phenotype, demon-
strating significant progress.
In conclusion, the efficient specification and superior
performance of stem cell-derived hepatocytes on laminin
substrates and their compatibility with GMP hESC lines
demonstrate an important advance. We believe that our
approach to hepatocyte differentiation will allow the
cost-effective production of GMP-grade hepatocytes at
scale that could ultimately be used in the clinic should
they deemed to be fit for the purpose.EXPERIMENTAL PROCEDURES
Cell Culture
H9, Man11, and Man12 (hESCs) were cultured as described previ-
ously (Szkolnicka et al., 2013) and maintained in a humidified
37C, 5%CO2 incubator. HumanESCswere plated onto pre-coated
Matrigel, 5 mg/cm2 laminin 521, or 5 mg/cm2 laminin 111 mix (a
blend of laminins 521 and 111 at a 1:3 ratio). This ratio was sug-
gested as optimal by the laminin supplier (Biolamina). Differenti-
ation was initiated at 40% confluence by replacing serum-free me-
dium mTESR1 (STEMCELL Technologies) with endoderm
differentiationmedium: RPMI 1640 containing 13 B27 (Life Tech-
nologies), 100 ng/mL Activin A (PeproTech), and 50 ng/mLWnt3a
(R&DSystems). Themediumwas changed every 24hr for 72 hr. On
day 4, endoderm differentiation medium was replaced with hepa-
toblast differentiation medium, and this was renewed every sec-
ond day for a further 5 days. The medium consisted of knockout
(KO)-DMEM (Life Technologies), Serum replacement (Life Tech-
nologies), 0.5% Glutamax (Life Technologies), 1% non-essential
amino acids (Life Technologies), 0.2% b-mercaptoethanol (Life
Technologies), and 1% DMSO (Sigma). On day 9, differentiating
cells were cultured in the hepatocyte maturation mediumHepato-
ZYME (Life Technologies) containing 1% Glutamax (Life Technol-
ogies), supplemented with 10 ng/ml hepatocyte growth factor
(PeproTech) and 20 ng/ml oncostatin m (PeproTech) as described
previously (Rodin et al., 2010; Szkolnicka et al., 2014b).
Primary Human Hepatocyte Culture
Cryoplateable human hepatocytes (Life Technologies) were
plated and maintained according to the vendor’s instructions.
Briefly, cryoplateable hepatocytes were resuscitated in thawing
medium (CM3000) and plated ontoMatrigel or laminin pre-coatedel. See Table S3 for a full list of gene and motif enrichment analyses
dent experiments. significant differences in mean gene expression
21, and laminin 111 in clusters 5, 10, and 6, which correspond to the
e Authors
96-well plates. Cells attached to all matrices efficiently and
were maintained in a humidified 37C, 5% CO2 incubator. 24 hr
after plating, the medium was changed to incubation medium
(CM4000). 48 hr after replating, hepatocyte metabolic activity
wasmeasured usingCYP3A4 andCYP1A2 pGlo technology (Prom-
ega) as described previously (Szkolnicka et al., 2014b).
Albumin and a Fetoprotein ELISA
hESC-derived and cryoplateable hepatocyte afetoprotein and albu-
min production was quantified using commercially available
ELISA kits (Alpha Diagnostic International). The different media
were collected at the denoted time points during hESC differentia-
tion (days 20–26). Primary hepatocyte medium was harvested
24 hr after plating onto Matrigel- or laminin-coated surfaces. Sam-
ples were run in triplicate and measured on a FLUOStar Omega
multi-mode microplate reader (BMG Labtech). Protein production
was expressed as nanogram or microgram of protein per milliliter
of medium per milligram of protein (bicinchoninic acid [BCA]
assay, Pierce).
RNA Isolation and qPCR
Total RNA was isolated from cells using Trizol reagent and
purified in accordance with the manufacturer’s instructions
(Life Technologies). RNA quantification and quality were as-
sessed using a Nanodrop system. The Superscript III reverse tran-
scription kit (Life Technologies) was employed to prepare the
cDNA. qPCR was performed with TaqMan Fast Advance Master-
mix and the appropriate primer pair (Applied Biosystems) and
analyzed using a Roche LightCycler 480 real-time PCR system.
Gene expression was normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and expressed as relative expression
over the control sample (hESC on day 0 of differentiation).
qPCRs were performed in triplicate. Data analysis was performed
using Roche LightCycler 480 software (version 1.5). Levels of
significance were measured by Student’s t test and defined as
p < 0.05.
Immunofluorescence
Throughout the differentiation process, cell cultures were fixed in
100% ice-cold methanol at 20C for 30 min. Subsequently, fixed
cells were washed twice with PBS at room temperature. Cell mono-
layers were blocked with 0.1% PBS-Tween containing 10% BSA for
1 hr, and subsequently the monolayers were incubated with pri-
mary antibodies diluted in PBS-0.1% Tween/1% BSA at 4C over-
night. The following day, the primary antibody was removed,
and the fixed monolayers were washed three times with PBS-
0.1% Tween/1% BSA. Following this, the cells were incubated
with the appropriate secondary antibody diluted in PBS/0.1%
Tween/1% BSA for 1 hr at room temperature and washed three
times with PBS. Cultures were then mounted with PermaFluor
aqueous mounting medium (Thermo Scientific) and counter-
stained with NucBlue Hoechst 33342 (Sigma-Aldrich). The cells
were imaged with an Axio Observer Z1 microscope with LD
PlanNeoFluar objective lenses (Carl Zeiss). This microscope was
coupled to a Zeiss AxioCamMR3 camera used for image acquisi-
tion. The images were processed through Zeiss Axiovision SE 64
Rel 4.8, with Zeiss Axiovision version 4.9.1.0 used to analyze theStem Cell Repimages. The percentage of positive cells and SD was estimated
from at least five random fields of view.
Cytochrome P450 Assays
CYP3A and CYP1A2 activity was measured from days 16–26 using
pGlo technology (Promega) and carried out according to the man-
ufacturer’s instructions for CYP450 activity estimation. CYP activ-
ity was expressed as relative light units (RLUs) per milliliter
of medium per milligram of protein (BCA assay, Pierce). Levels of
significance were measured by Student’s t test. The experiments
with hESC-derived hepatocytes are representative of six biological
replicates, whereas the primary human hepatocyte experiments
are representative of three biological replicates.
Functional Polarization Assay
hESC-derived hepatocytes were incubatedwith 2 mMofCDFDA for
30 min. Cultures were then washed with ice-cold phosphate-buff-
ered saline containing calcium and magnesium. After washing,
stem cell-derived hepatocytes were counterstained with DAPI
and collected for imaging. CDFDA efflux from canalicular like
structures was examined microscopically.
Gene Microarray and Bioinformatics Studies
Gene microarrays and bioinformatics studies were compared and
performed as described previously (Godoy et al., 2015). The ex-
tracts used in these studies pertain to day 24 stem cell-derived
HLCs on Matrigel, LN521, and the LN111 mix.
ACCESSION NUMBERS
The accession number for the microarray data reported in this
paper is EMBL-EBI: E-MTAB-3994.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and three tables
and can be found with this article online at http://dx.doi.org/10.
1016/j.stemcr.2015.10.016.
AUTHOR CONTRIBUTIONS
K.C. designed, performed, and analyzed the experiments and
contributed to the writing of the paper. R.T. performed and
analyzed the experiments. Y.W., B.L.V., and D.S. optimized previ-
ous and validated new procedures presented in this manuscript.
G.C. and W.S.H. performed and analyzed microarray and qPCR
data. P.G and J.G.H. analyzed microarray and qPCR data and
contributed to the writing of the manuscript. M.J.L. carried out
experimental statistical analysis. N.B. and S.J.K. derived and pro-
vided the GMP-grade cell lines Man11 and Man12. S.J.F provided
funding, analyzed experiments, and contributed to the writing
of the paper. D.C.H led the conception, design, and analysis of
the experiments; wrote the manuscript; and provided funding.
ACKNOWLEDGMENTS
We thank Ms. Katharina Rochlitz for technical support. We
are grateful to Dr. Maurice Canham for his help with theManches-
ter hESC lines. K.C., D.C.H., and S.J.F. were supported by UKorts j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 The Authors 1259
Regenerative Medicine Platform grants MR/K026666/1 and MR/
L022974/1. R.T. was a self-funded visiting masters student. B.L.V.
andD.S. were supported byMRCPh.D. studentships. Y.W.was sup-
ported by a China scholarship. S.J.K. and N.B. were supported by
the MRC (G0801057) and the BBSRC/TSB (BB/J021636/1). M.J.L.
was supported by the Wellcome Trust (102839/Z/13/Z). P.G.,
W.S.H., J.G.H., and G.C. were supported by the European Union
Seventh Framework Programme (FP7) Health Projects DETECTIVE
(EU Project FP7HealthGrant Agreement 266838) andNOTOX (EU
Project FP7 Health Grant Agreement267038) and the BMBF
(German Federal Ministry of Education and Research) Project Vir-
tual Liver (0313854).
Received: October 1, 2015
Revised: October 28, 2015
Accepted: October 29, 2015
Published: November 25, 2015REFERENCES
Basma, H., Soto-Gutie´rrez, A., Yannam, G.R., Liu, L., Ito, R., Yama-
moto, T., Ellis, E., Carson, S.D., Sato, S., Chen, Y., et al. (2009).
Differentiation and transplantation of human embryonic stem
cell-derived hepatocytes. Gastroenterology 136, 990–999.
Cahan, P., Li, H., Morris, S.A., Lummertz da Rocha, E., Daley, G.Q.,
and Collins, J.J. (2014). CellNet: network biology applied to stem
cell engineering. Cell 158, 903–915.
Cai, J., Zhao, Y., Liu, Y., Ye, F., Song, Z., Qin, H., Meng, S., Chen, Y.,
Zhou, R., Song, X., et al. (2007). Directed differentiation of human
embryonic stem cells into functional hepatic cells. Hepatology 45,
1229–1239.
Cameron, K., Villarin, B.L., Szkolnicka, D., and Hay, D.C. (2015).
Serum-free directed differentiation of human embryonic stem cells
to hepatocytes. In Protocols in In Vitro Hepatocyte Research, M.
Vinken and V. Rogiers, eds. (Humana Press), pp. 105–111.
Carlsson, R., Engvall, E., Freeman, A., and Ruoslahti, E. (1981).
Laminin and fibronectin in cell adhesion: enhanced adhesion of
cells from regenerating liver to laminin. Proc. Natl. Acad. Sci.
USA 78, 2403–2406.
Carpentier, A., Tesfaye, A., Chu, V., Nimgaonkar, I., Zhang, F., Lee,
S.B., Thorgeirsson, S.S., Feinstone, S.M., and Liang, T.J. (2014).
Engrafted human stem cell-derived hepatocytes establish an infec-
tious HCV murine model. J. Clin. Invest. 124, 4953–4964.
Domogatskaya, A., Rodin, S., and Tryggvason, K. (2012). Func-
tional diversity of laminins. Annu. Rev. Cell Dev. Biol. 28, 523–553.
Duan, Y., Catana, A., Meng, Y., Yamamoto, N., He, S., Gupta, S.,
Gambhir, S.S., and Zern, M.A. (2007). Differentiation and enrich-
ment of hepatocyte-like cells from human embryonic stem cells
in vitro and in vivo. Stem Cells 25, 3058–3068.
Forbes, S.J., Gupta, S., andDhawan, A. (2015). Cell therapy for liver
disease: From liver transplantation to cell factory. J. Hepatol. 62 (1,
Suppl), S157–S169.
Gadi, J., Jung, S.H., Lee, M.J., Jami, A., Ruthala, K., Kim, K.M., Cho,
N.H., Jung, H.S., Kim, C.H., and Lim, S.K. (2013). The transcription
factor protein Sox11 enhances early osteoblast differentiation by1260 Stem Cell Reports j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 Thfacilitating proliferation and the survival of mesenchymal and
osteoblast progenitors. J. Biol. Chem. 288, 25400–25413.
Godoy, P., Hengstler, J.G., Ilkavets, I., Meyer, C., Bachmann, A.,
Mu¨ller, A., Tuschl, G., Mueller, S.O., and Dooley, S. (2009).
Extracellular matrix modulates sensitivity of hepatocytes to fibro-
blastoid dedifferentiation and transforming growth factor beta-
induced apoptosis. Hepatology 49, 2031–2043.
Godoy, P., Lakkapamu, S., Schug, M., Bauer, A., Stewart, J.D.,
Bedawi, E., Hammad, S., Amin, J., Marchan, R., Schormann, W.,
et al. (2010). Dexamethasone-dependent versus -independent
markers of epithelial to mesenchymal transition in primary hepa-
tocytes. Biol. Chem. 391, 73–83.
Godoy, P., Schmidt-Heck, W., Natarajan, K., Lucendo-Villarin, B.,
Szkolnicka, D., Asplund, A., Bjo¨rquist, P., Widera, A., Sto¨ber, R.,
Campos, G., et al. (2015). Gene networks and transcription factor
motifs defining the differentiation of stem cells into hepatocyte-
like cells. J. Hepatol. 63, 934–942.
Hay, D.C., Zhao, D., Ross, A.,Mandalam, R., Lebkowski, J., andCui,
W. (2007). Direct differentiation of human embryonic stem cells to
hepatocyte-like cells exhibiting functional activities. Cloning Stem
Cells 9, 51–62.
Hay, D.C., Fletcher, J., Payne, C., Terrace, J.D., Gallagher, R.C.,
Snoeys, J., Black, J.R., Wojtacha, D., Samuel, K., Hannoun, Z.,
et al. (2008). Highly efficient differentiation of hESCs to functional
hepatic endoderm requires ActivinA and Wnt3a signaling. Proc.
Natl. Acad. Sci. USA 105, 12301–12306.
Hay, D.C., Pernagallo, S., Diaz-Mochon, J.J., Medine, C.N., Green-
hough, S., Hannoun, Z., Schrader, J., Black, J.R., Fletcher, J., Dal-
getty, D., et al. (2011). Unbiased screening of polymer libraries to
define novel substrates for functional hepatocytes with inducible
drug metabolism. Stem Cell Res. (Amst.) 6, 92–102.
Holl, D., Kuckenberg, P., Woynecki, T., Egert, A., Becker, A., Huss,
S., Stabenow, D., Zimmer, A., Knolle, P., Tolba, R., et al. (2011).
Transgenic overexpression of Tcfap2c/AP-2gamma results in liver
failure and intestinal dysplasia. PLoS ONE 6, e22034.
Holmgren, G., Sjo¨gren, A.K., Barragan, I., Sabirsh, A., Sartipy, P.,
Synnergren, J., Bjo¨rquist, P., Ingelman-Sundberg, M., Andersson,
T.B., and Edsbagge, J. (2014). Long-term chronic toxicity testing
using human pluripotent stem cell-derived hepatocytes. Drug
Metab. Dispos. 42, 1401–1406.
Jitraruch, S., Dhawan, A., Hughes, R.D., Filippi, C., Soong, D., Phil-
ippeos, C., Lehec, S.C., Heaton, N.D., Longhi, M.S., andMitry, R.R.
(2014). Alginate microencapsulated hepatocytes optimised for
transplantation in acute liver failure. PLoS ONE 9, e113609.
Karpen, S.J., and Suchy, F.J. (2001). Structural and functional devel-
opment of the liver. In Liver Disease in Children, F.J. Suchy, R.J.
Sokol, and W.F. Balistreri, eds. (Lippincott Williams & Wilkins).
Lavon, N., Yanuka, O., and Benvenisty, N. (2004). Differentiation
and isolation of hepatic-like cells from human embryonic stem
cells. Differentiation 72, 230–238.
Lee, S.Y., Lee, G.R., Woo, D.H., Park, N.H., Cha, H.J., Moon, Y.H.,
and Han, I.S. (2013). Depletion of Aurora A leads to upregulation
of FoxO1 to induce cell cycle arrest in hepatocellular carcinoma
cells. Cell Cycle 12, 67–75.e Authors
Lorenzini, S., Bird, T.G., Boulter, L., Bellamy, C., Samuel, K., Aucott,
R., Clayton, E., Andreone, P., Bernardi, M., Golding, M., et al.
(2010). Characterisation of a stereotypical cellular and extracel-
lular adult liver progenitor cell niche in rodents and diseased hu-
man liver. Gut 59, 645–654.
Martinez-Hernandez, A., and Amenta, P.S. (1993a). The hepatic
extracellular matrix. I. Components and distribution in normal
liver. Virchows Arch. A Pathol. Anat. Histopathol. 423, 1–11.
Martinez-Hernandez, A., and Amenta, P.S. (1993b). The hepatic
extracellular matrix. II. Ontogenesis, regeneration and cirrhosis.
Virchows Arch. A Pathol. Anat. Histopathol. 423, 77–84.
Martinez-Hernandez, A., andAmenta, P.S. (1995). The extracellular
matrix in hepatic regeneration. FASEB J. 9, 1401–1410.
Medine, C.N., Lucendo-Villarin, B., Storck, C., Wang, F., Szkol-
nicka, D., Khan, F., Pernagallo, S., Black, J.R., Marriage, H.M.,
Ross, J.A., et al. (2013). Developing high-fidelity hepatotoxicity
models from pluripotent stem cells. Stem Cells Transl. Med. 2,
505–509.
Miner, J.H., Li, C., Mudd, J.L., Go, G., and Sutherland, A.E. (2004).
Compositional and structural requirements for laminin and base-
ment membranes during mouse embryo implantation and gastru-
lation. Development 131, 2247–2256.
Morris, S.A., Cahan, P., Li, H., Zhao, A.M., San Roman, A.K., Shiv-
dasani, R.A., Collins, J.J., and Daley, G.Q. (2014). Dissecting engi-
neered cell types and enhancing cell fate conversion via CellNet.
Cell 158, 889–902.
Ng, S., Schwartz, R.E., March, S., Galstian, A., Gural, N., Shan, J.,
Prabhu, M., Mota, M.M., and Bhatia, S.N. (2015). Human iPSC-
derived hepatocyte-like cells support Plasmodium liver-stage infec-
tion in vitro. Stem Cell Reports 4, 348–359.
Payne, C.M., Samuel, K., Pryde, A., King, J., Brownstein, D.,
Schrader, J., Medine, C.N., Forbes, S.J., Iredale, J.P., Newsome,
P.N., and Hay, D.C. (2011). Persistence of functional hepatocyte-
like cells in immune-compromised mice. Liver Int. 31, 254–262.
Rashid, S.T., Corbineau, S., Hannan, N., Marciniak, S.J., Miranda,
E., Alexander, G., Huang-Doran, I., Griffin, J., Ahrlund-Richter,
L., Skepper, J., et al. (2010).Modeling inheritedmetabolic disorders
of the liver using human induced pluripotent stem cells. J. Clin.
Invest. 120, 3127–3136.
Rodin, S., Domogatskaya, A., Stro¨m, S., Hansson, E.M., Chien, K.R.,
Inzunza, J., Hovatta, O., and Tryggvason, K. (2010). Long-term self-
renewal of human pluripotent stem cells on human recombinant
laminin-511. Nat. Biotechnol. 28, 611–615.
Roelandt, P., Obeid, S., Paeshuyse, J., Vanhove, J., Van Lommel, A.,
Nahmias, Y., Nevens, F., Neyts, J., and Verfaillie, C.M. (2012). Hu-
man pluripotent stem cell-derived hepatocytes support complete
replication of hepatitis C virus. J. Hepatol. 57, 246–251.
Schwartz, R.E., Fleming, H.E., Khetani, S.R., and Bhatia, S.N.
(2014). Pluripotent stem cell-derived hepatocyte-like cells. Bio-
technol. Adv. 32, 504–513.
Si-Tayeb, K., Noto, F.K., Nagaoka, M., Li, J., Battle, M.A., Duris, C.,
North, P.E., Dalton, S., and Duncan, S.A. (2010). Highly efficient
generation of human hepatocyte-like cells from induced pluripo-
tent stem cells. Hepatology 51, 297–305.Stem Cell RepSiller, R., Greenhough, S., Naumovska, E., and Sullivan,G.J. (2015).
Small-molecule-driven hepatocyte differentiation of human
pluripotent stem cells. Stem Cell Reports 4, 939–952.
Sirma, H., Kumar, M., Meena, J.K., Witt, B., Weise, J.M., Lechel, A.,
Ande, S., Sakk, V., Guguen-Guillouzo, C., Zender, L., et al. (2011).
The promoter of human telomerase reverse transcriptase is acti-
vated during liver regeneration and hepatocyte proliferation.
Gastroenterology 141, 326–337, 337.e1–337.e3.
Stamatoglou, S.C., Enrich, C., Manson, M.M., and Hughes, R.C.
(1992). Temporal changes in the expression and distribution of
adhesion molecules during liver development and regeneration.
J. Cell Biol. 116, 1507–1515.
Sullivan, G.J., Hay, D.C., Park, I.H., Fletcher, J., Hannoun, Z.,
Payne, C.M., Dalgetty, D., Black, J.R., Ross, J.A., Samuel, K., et al.
(2010). Generation of functional human hepatic endoderm from
human induced pluripotent stem cells. Hepatology 51, 329–335.
Sun, P., Zhou,X., Farnworth, S.L., Patel, A.H., andHay, D.C. (2013).
Modeling human liver biology using stem cell-derived hepato-
cytes. Int. J. Mol. Sci. 14, 22011–22021.
Szkolnicka, D., Zhou, W., Lucendo-Villarin, B., and Hay, D.C.
(2013). Pluripotent stem cell-derived hepatocytes: potential and
challenges in pharmacology. Annu. Rev. Pharmacol. Toxicol. 53,
147–159.
Szkolnicka, D., Farnworth, S.L., Lucendo-Villarin, B., andHay, D.C.
(2014a). Deriving functional hepatocytes from pluripotent stem
cells. Curr. Protoc. Stem Cell Biol. 30, 1–12, 12.
Szkolnicka, D., Farnworth, S.L., Lucendo-Villarin, B., Storck, C.,
Zhou, W., Iredale, J.P., Flint, O., and Hay, D.C. (2014b). Accurate
prediction of drug-induced liver injury using stem cell-derived
populations. Stem Cells Transl. Med. 3, 141–148.
Takayama, K., Nagamoto, Y., Mimura, N., Tashiro, K., Sakurai, F.,
Tachibana, M., Hayakawa, T., Kawabata, K., and Mizuguchi, H.
(2013a). Long-term self-renewal of human ES/iPS-derived hepato-
blast-like cells on human laminin 111-coated dishes. Stem Cell
Reports 1, 322–335.
Takayama, K., Kawabata, K., Nagamoto, Y., Kishimoto, K., Tashiro,
K., Sakurai, F., Tachibana,M., Kanda, K., Hayakawa, T., Furue,M.K.,
and Mizuguchi, H. (2013b). 3D spheroid culture of hESC/hiPSC-
derived hepatocyte-like cells for drug toxicity testing. Biomaterials
34, 1781–1789.
Tanimizu, N., Kikkawa, Y., Mitaka, T., andMiyajima, A. (2012). a1-
and a5-containing laminins regulate the development of bile ducts
via b1 integrin signals. J. Biol. Chem. 287, 28586–28597.
Taylor-Weiner, H., Schwarzbauer, J.E., and Engler, A.J. (2013).
Defined extracellular matrix components are necessary for defini-
tive endoderm induction. Stem Cells 31, 2084–2094.
Touboul, T., Hannan, N.R., Corbineau, S., Martinez, A., Martinet,
C., Branchereau, S., Mainot, S., Strick-Marchand, H., Pedersen,
R., Di Santo, J., et al. (2010). Generation of functional hepatocytes
from human embryonic stem cells under chemically defined
conditions that recapitulate liver development. Hepatology 51,
1754–1765.
Treyer, A., and Mu¨sch, A. (2013). Hepatocyte polarity. Compr.
Physiol. 3, 243–287.orts j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 The Authors 1261
Villarin, B.L., Cameron, K., Szkolnicka, D., Rashidi, H., Bates, N.,
Kimber, S.J., Flint, O., Forbes, S.J., Iredale, J.P., Bradley, M., and
Hay, D.C. (2015). Polymer Supported Directed Differentiation
Reveals a Unique Gene Signature Predicting Stable Hepatocyte
Performance. Adv. Healthc. Mater. 4, 1820–1825.
Ware, B.R., Berger, D.R., and Khetani, S.R. (2015). Prediction of
drug-induced liver injury in micropatterned co-cultures contain-
ing iPSC-derived human hepatocytes. Toxicol. Sci. 145, 252–262.
http://dx.doi.org/10.1093/toxsci/kfv048.
Wu, X., Robotham, J.M., Lee, E., Dalton, S., Kneteman, N.M.,
Gilbert, D.M., and Tang, H. (2012). Productive hepatitis C virus
infection of stem cell-derived hepatocytes reveals a critical transi-1262 Stem Cell Reports j Vol. 5 j 1250–1262 j December 8, 2015 j ª2015 Thtion to viral permissiveness during differentiation. PLoS Pathog.
8, e1002617.
Zhou,W., Hannoun, Z., Jaffray, E.,Medine, C.N., Black, J.R., Green-
hough, S., Zhu, L., Ross, J.A., Forbes, S., Wilmut, I., et al. (2012).
SUMOylation of HNF4a regulates protein stability and hepatocyte
function. J. Cell Sci. 125, 3630–3635.
Zhou, X., Sun, P., Lucendo-Villarin, B., Angus, A.G.N., Szkolnicka,
D., Cameron, K., Farnworth, S.L., Patel, A.H., andHay, D.C. (2014).
Modulating innate immunity improves hepatitis C virus infection
and replication in stem cell-derived hepatocytes. StemCell Reports
3, 204–214.e Authors
